Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

Stock Information for China SXT Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About China SXT Pharmaceuticals Inc.

Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data
Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD)
Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108
Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108
Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China
Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million
Palisade Bio Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.